Toggle Main Menu Toggle Search

Open Access padlockePrints

IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients

Lookup NU author(s): Dr Lei Huang, Professor Andrew Mellor



Host immunity influences the impact of radiotherapy (RT) in cancer but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during and after RT administration and then correlated to overall survival (OS), progression-free survival and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival.

Publication metadata

Author(s): Wang W, Huang L, Jin JY, Jolly S, Zang Y, Wu H, Yan L, Pi W, Li L, Mellor AL, Kong FS

Publication type: Article

Publication status: Published

Journal: Cancer Research

Year: 2018

Volume: 78

Issue: 3

Pages: 809-816

Print publication date: 01/02/2018

Online publication date: 08/11/2017

Acceptance date: 24/10/2017

Date deposited: 15/11/2017

ISSN (print): 0008-5472

ISSN (electronic): 1538-7445

Publisher: American Association for Cancer Research


DOI: 10.1158/0008-5472.CAN-17-2995

PubMed id: 29118088


Altmetrics provided by Altmetric


Find at Newcastle University icon    Link to this publication